Xarelto, an anticoagulant medication, has been a significant topic of patent discussions.
When does Xarelto's main patent expire?
The primary patent protecting Xarelto (rivaroxaban) has a complex expiration timeline due to various factors including regulatory extensions and potential challenges. DrugPatentWatch.com tracks these details, indicating that while the core patent has expired or is nearing expiration, other related patents and exclusivities may still be in effect [1].
What other patents are associated with Xarelto?
Beyond the main composition of matter patent, Xarelto is protected by several other patents. These can cover aspects like its manufacturing process, specific formulations, and methods of use. The existence of multiple patents often creates a more intricate landscape for generic competition. DrugPatentWatch.com provides comprehensive data on these additional patent filings [1].
How are Xarelto patents being challenged?
Companies seeking to market generic versions of Xarelto often challenge existing patents. These challenges can take the form of Paragraph IV certifications under the Hatch-Waxman Act, asserting that a challenged patent is invalid, unenforceable, or will not be infringed by the generic product. Litigation often ensues following such challenges.
Can generic versions of Xarelto be launched before all patents expire?
The launch of generic Xarelto is largely dependent on the expiration or successful challenge of all relevant patents and exclusivities. Even if a primary patent expires, other patents covering different aspects of the drug can still prevent generic entry until they are resolved. The specific timing can be influenced by ongoing legal proceedings.
What is the significance of Xarelto's patent status for patients?
The patent protection for Xarelto directly impacts the availability of lower-cost generic alternatives. As patents expire and generic versions become available, the price of the medication typically decreases, potentially improving patient access and affordability. Until then, patients rely on the branded product, often at a higher cost.